Target specificity of 188Re-labeled B27.1 monoclonal antibodies to ovarian cancer cells in vivo. Academic Article uri icon


  • BACKGROUND: Currently we are exploring a new multistep pretargeting approach involving administration of a bispecific antibody (B27.1 x P54) which has an anti-CA-125 (B27.1) and antibiotin (P54) paratope. It is followed by the administration of radiolabeled biotinylated liposomes to target the 188Re to the ovarian cancer cells. As a preliminary step to realize this goal, we determined the target specificity of the monoclonal antibodies (B27.1) to the ovarian cancer cells in vivo. MATERIALS AND METHODS: B27.1 monoclonal antibodies were photoreduced using UV light and incubated with reduced 188Re for 30 min at 25degreesC. 188Re-labeled B27.1 antibodies were purified using size exclusion chromatography. A comparative biodistribution of Re-B27.1 and 188Re was performed in nude mice xenografted with NIH:OVCAR-3 cells. RESULTS: While free rhenium distributed preferentially into thyroid and stomach with insignificant accumulation in the cancer cells, about 20% of the injected dose of 188Re-B27.1 was recovered in ascites cells with insignificant localization in other organs four hours after administration. CONCLUSION: The study validates the affinity of the B27.1 antibodies to the ovarian cancer cells in vivo.

published proceedings

  • In Vivo

author list (cited authors)

  • Palakurthi, S., Wilson, J., McQuarrie, S. A., Suresh, M. R., Mercer, J. R., & Miller, G. G.

citation count

  • 2

complete list of authors

  • Palakurthi, Srinath||Wilson, John||McQuarrie, Steve A||Suresh, Mavanur R||Mercer, John R||Miller, Gerald G

publication date

  • May 2008